Search

Your search keyword '"Mo, Clifton C."' showing total 173 results
Start Over Author "Mo, Clifton C."
173 results on '"Mo, Clifton C."'

2. Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide

Author

Mo, Clifton C., Richardson, Edward, Calabretta, Eleonora, Corrado, Francesco, Kocoglu, Mehmet H., Baron, Rebecca M., Connors, Jean Marie, Iacobelli, Massimo, Wei, Lee-Jen, Rapoport, Aaron P., Díaz-Ricart, Maribel, Moraleda, José M., Carlo-Stella, Carmelo, and Richardson, Paul G.

Published
2024
Full Text
View/download PDF

3. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma

Author

O'Donnell, Elizabeth K., Shapiro, Yael N., Yee, Andrew J., Nadeem, Omar, Laubach, Jacob P., Branagan, Andrew R., Anderson, Kenneth C., Mo, Clifton C., Munshi, Nikhil C., Ghobrial, Irene M., Sperling, Adam S., Agyemang, Emerentia A., Burke, Jill N., Harrington, Cynthia C., Hu, Bonnie Y., Richardson, Paul G., Raje, Noopur S., and El-Jawahri, Areej

Published
2022
Full Text
View/download PDF

4. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study

Author

El-Khoury, Habib, Lee, David J, Alberge, Jean-Baptiste, Redd, Robert, Cea-Curry, Christian J, Perry, Jacqueline, Barr, Hadley, Murphy, Ciara, Sakrikar, Dhananjay, Barnidge, David, Bustoros, Mark, Leblebjian, Houry, Cowan, Anna, Davis, Maya I, Amstutz, Julia, Boehner, Cody J, Lightbody, Elizabeth D, Sklavenitis-Pistofidis, Romanos, Perkins, Mark C, Harding, Stephen, Mo, Clifton C, Kapoor, Prashant, Mikhael, Joseph, Borrello, Ivan M, Fonseca, Rafael, Weiss, Scott T, Karlson, Elizabeth, Trippa, Lorenzo, Rebbeck, Timothy R, Getz, Gad, Marinac, Catherine R, and Ghobrial, Irene M

Published
2022
Full Text
View/download PDF

11. Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs

Author

Massachusetts Institute of Technology. Laser Biomedical Research Center, Liu, Xili, Moscvin, Maria, Oh, Seungeun, Chen, Tianzeng, Choi, Wonshik, Evans, Benjamin, Rowell, Sean M., Nadeem, Omar, Mo, Clifton C., Sperling, Adam S., Anderson, Kenneth C., Yaqoob, Zahid, Bianchi, Giada, Sung, Yongjin, Massachusetts Institute of Technology. Laser Biomedical Research Center, Liu, Xili, Moscvin, Maria, Oh, Seungeun, Chen, Tianzeng, Choi, Wonshik, Evans, Benjamin, Rowell, Sean M., Nadeem, Omar, Mo, Clifton C., Sperling, Adam S., Anderson, Kenneth C., Yaqoob, Zahid, Bianchi, Giada, and Sung, Yongjin

Abstract

Multiple myeloma (MM) is a cancer of terminally differentiated plasma cells. MM remains incurable, but overall survival of patients has progressively increased over the past two decades largely due to novel agents such as proteasome inhibitors (PI) and the immunomodulatory agents. While these therapies are highly effective, MM patients can be de novo resistant and acquired resistance with prolonged treatment is inevitable. There is growing interest in early, accurate identification of responsive versus non-responsive patients; however, limited sample availability and need for rapid assays are limiting factors. Here, we test dry mass and volume as label-free biomarkers to monitor early response of MM cells to treatment with bortezomib, doxorubicin, and ultraviolet light. For the dry mass measurement, we use two types of phase-sensitive optical microscopy techniques: digital holographic tomography and computationally enhanced quantitative phase microscopy. We show that human MM cell lines (RPMI8226, MM.1S, KMS20, and AMO1) increase dry mass upon bortezomib treatment. This dry mass increase after bortezomib treatment occurs as early as 1 h for sensitive cells and 4 h for all tested cells. We further confirm this observation using primary multiple myeloma cells derived from patients and show that a correlation exists between increase in dry mass and sensitivity to bortezomib, supporting the use of dry mass as a biomarker. The volume measurement using Coulter counter shows a more complex behavior; RPMI8226 cells increase the volume at an early stage of apoptosis, but MM.1S cells show the volume decrease typically observed with apoptotic cells. Altogether, this cell study presents complex kinetics of dry mass and volume at an early stage of apoptosis, which may serve as a basis for the detection and treatment of MM cells.

Published
2023

12. Prehabilitation Exercise Training to Target Improved Muscle Strength in Pretransplant Patients Diagnosed With Multiple Myeloma: Protocol for a Pilot Randomized Controlled Trial.

Author

Normann, Amber J, Mo, Clifton C, Wilson, Rebekah L, Perez, Michelle, Cutler, Corey, Uno, Hajime, Thompson, LaDora V, Skinner, Tina L, Richardson, Paul G, Marinac, Catherine R, and Dieli-Conwright, Christina M

Subjects
MUSCLE mass, MYELOMA proteins, STEM cell transplantation, AEROBIC exercises, MUSCLE strength
Abstract

Background: Muscle mass and strength are severely compromised in patients diagnosed with multiple myeloma, such that the risk of poor overall survival increases as the prevalence of low muscle mass, also known as sarcopenia, increases. Additionally, at the time of autologous stem cell transplant (ASCT), 51% of patients experience low muscle mass and strength, which can prolong hospitalization and lead to increased risk of obesity, insulin resistance, lowered physical function, and poor quality of life. Objective: The PROTECT (Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation) trial will examine the preliminary effects of digitally supervised prehabilitative aerobic and resistance exercise on muscle strength in patients with multiple myeloma scheduled for ASCT. Methods: This prospective, 2-armed single-center randomized controlled trial will recruit 30 patients with multiple myeloma, aged 18 years and older, planning to receive ASCT. Individuals will be assigned to either the exercise or the waitlist control group. The 8-week exercise intervention is home-based and digitally supervised by a clinical exercise trainer. The frequency of the exercise intervention is 3 times per week consisting of aerobic exercise on a cycle ergometer and resistance exercises, which are individually tailored based on patient health status. The waitlist control group maintains normal daily activities of living and is offered the intervention within 6 months from ASCT. The primary outcome is lower limb muscle strength, measured using the 10-repetition maximum leg press or extensor strength. Additional outcomes include physical and cardiorespiratory function, patient-reported outcomes, cardiometabolic health outcomes, and clinical outcomes. Results: The trial was funded in the fall of 2022 and recruitment began in June 2023. As of August 2024, a total of 3 participants have consented and been randomized (n=1, exercise group; n=2, waitlist control group). Trial completion and start of data analysis is expected in July 2025 with expected results to be published in early winter of 2026. Conclusions: We expect exercise to improve lower limb muscle strength and overall health outcomes compared to the waitlist control group. Results will contribute foundational knowledge needed to conduct larger-phase clinical trials testing the clinical benefits of prehabilitation exercise in this patient population. This study will provide insight into a prehabilitative exercise intervention designed to support patient prognosis. Trial Registration: ClinicalTrials.gov NCT05706766; https://clinicaltrials.gov/study/NCT05706766 International Registered Report Identifier (IRRID): DERR1-10.2196/64905 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Selinexor: Targeting a novel pathway in multiple myeloma

Author

Mo, Clifton C., primary, Yee, Andrew J., additional, Midha, Shonali, additional, Hartley‐Brown, Monique A., additional, Nadeem, Omar, additional, O'Donnell, Elizabeth K., additional, Bianchi, Giada, additional, Sperling, Adam S., additional, Laubach, Jacob P., additional, and Richardson, Paul G., additional

Published
2023
Full Text
View/download PDF

14. Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted Therapy.

Author

Mo, Clifton C., Hartley-Brown, Monique A., Midha, Shonali, and Richardson, Paul G.

Subjects
*STEM cell transplantation, *MULTIPLE myeloma treatment, *MULTIPLE myeloma diagnosis, *MELPHALAN, *AUTOGRAFTS, *TREATMENT effectiveness, *PROGRESSION-free survival, *INDUCTION chemotherapy, *OVERALL survival
Abstract

Simple Summary: Patients who are diagnosed with multiple myeloma are given an initial sequence of treatments that usually, for those who are young and fit enough, includes high-dose melphalan followed by autologous stem cell transplantation. This has contributed to the improvement in survival seen over the past 30 years. However, high-dose melphalan has significant limitations, including short-term side effects and longer-term issues such as an increased risk of developing secondary hematologic malignancies including leukemia. There are now numerous highly efficacious combination regimens for initial treatment that result in increasingly large proportions of patients achieving deep responses with no evidence of minimal residual disease. Moreover, large, randomized studies using these regimens have shown no benefit in overall survival after receiving high-dose melphalan with stem cell transplantation. There is thus a growing rationale for selected eligible patients to defer receiving high-dose melphalan and stem cell transplantation until potentially needed in a subsequent line of treatment. The standards of care for the initial treatment of patients with newly diagnosed multiple myeloma (NDMM) who are eligible for high-dose melphalan and autologous stem cell transplantation (HDM-ASCT) include highly active triplet and quadruplet regimens based on proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. These regimens are resulting in improved outcomes and increasingly high rates of minimal residual disease (MRD)-negative responses without HDM-ASCT as part of the upfront therapy. Furthermore, recent randomized studies have shown that, while transplant-based approaches as a frontline therapy result in significantly longer progression-free survival compared to non-transplant approaches, this has not translated into an overall survival benefit. Given these developments, and in the context of the treatment burden of undergoing HDM-ASCT, in addition to the acute toxicities and long-term sequelae of HDM, which are associated with the genotoxicity of melphalan, there is an increasing rationale for considering deferring upfront HDM-ASCT in select transplant-eligible patients and saving it as a treatment option for later salvage therapy. Here, we review the latest clinical trial data on upfront or deferred HDM-ASCT and on the activity of quadruplet induction regimens, including rates of MRD-negative responses, and summarize emerging treatment approaches in the upfront setting such as the use of MRD-directed therapy and alternatives to HDM-ASCT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

Author

Branagan, Andrew R., primary, Lei, Matthew M, additional, Mo, Clifton C, additional, Yee, Andrew J., additional, O'Donnell, Elizabeth K., additional, Castillo, Jorge J., additional, Nadeem, Omar, additional, Raje, Noopur, additional, Treon, Steven P, additional, Richardson, Paul G., additional, Nakamoto-Matsubara, Rie, additional, Meid, Kirsten, additional, Bernstein, Zachary S., additional, Lyons, Rebecca T., additional, Verma, Rakesh, additional, Hunter, Zachary R, additional, Guerrera, Maria Luisa, additional, Flynn, Catherine A., additional, Burke, Jill N., additional, Harrington, Cynthia C., additional, Agyemang, Emerentia, additional, Gammon, Marilyn T., additional, Lively, Kathleen J., additional, Packer, Lisette, additional, Horick, Nora K., additional, and Sarosiek, Shayna, additional

Published
2022
Full Text
View/download PDF

16. A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Author

O'Donnell, Elizabeth K., primary, Mo, Clifton C, additional, Nadeem, Omar, additional, Yee, Andrew J., additional, Branagan, Andrew R., additional, Laubach, Jacob, additional, Gammon, Marilyn T., additional, Lively, Kathleen J., additional, Packer, Lisette, additional, Harrington, Cynthia C., additional, Agyemang, Emerentia, additional, Rosenblatt, Jacalyn, additional, Horick, Nora K., additional, Richardson, Paul G., additional, and Raje, Noopur, additional

Published
2022
Full Text
View/download PDF

17. A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Author

Nadeem, Omar, primary, Redd, Robert A., additional, Bayliss, Trevor J., additional, Barth, Peter, additional, Laubach, Jacob, additional, Mo, Clifton C., additional, Bianchi, Giada, additional, Masone, Kelly, additional, Griffin, Kyle, additional, Issokson, Lindsay, additional, Barrell, Anna, additional, Doherty, Randi, additional, Mailand, Deborah, additional, Distaso, Alexandra, additional, Patches, Sarah, additional, Goodrich, Kathryn, additional, Oneill, Kathleen, additional, Sanchorawala, Vaishali, additional, Shune, Leyla O., additional, and Richardson, Paul G., additional

Published
2022
Full Text
View/download PDF

18. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma

Author

O’Donnell, Elizabeth K., primary, Shapiro, Yael N., additional, Yee, Andrew J., additional, Nadeem, Omar, additional, Laubach, Jacob P., additional, Branagan, Andrew R., additional, Anderson, Kenneth C., additional, Mo, Clifton C., additional, Munshi, Nikhil C., additional, Ghobrial, Irene M., additional, Sperling, Adam S., additional, Agyemang, Emerentia A., additional, Burke, Jill N., additional, Harrington, Cynthia C., additional, Hu, Bonnie Y., additional, Richardson, Paul G., additional, Raje, Noopur S., additional, and El-Jawahri, Areej, additional

Published
2022
Full Text
View/download PDF

19. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation

Author

Pérez-Galán, Patricia, Mora-Jensen, Helena, Weniger, Marc A., Shaffer, Arthur L., III, Rizzatti, Edgar G., Chapman, Colby M., Mo, Clifton C., Stennett, Lawrence S., Rader, Christoph, Liu, Poching, Raghavachari, Nalini, Stetler-Stevenson, Maryalice, Yuan, Constance, Pittaluga, Stefania, Maric, Irina, Dunleavy, Kieron M., Wilson, Wyndham H., Staudt, Louis M., and Wiestner, Adrian

Published
2011
Full Text
View/download PDF

20. Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs

Author

Liu, Xili, primary, Moscvin, Maria, additional, Oh, Seungeun, additional, Chen, Tianzeng, additional, Choi, Wonshik, additional, Evans, Benjamin, additional, Rowell, Sean M, additional, Nadeem, Omar, additional, Mo, Clifton C., additional, Sperling, Adam S., additional, Anderson, Kenneth C., additional, Yaqoob, Zahid, additional, Bianchi, Giada, additional, and Sung, Yongjin, additional

Published
2022
Full Text
View/download PDF

21. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma

Author

O’Donnell, Elizabeth K., primary, Shapiro, Yael N., additional, Yee, Andrew J., additional, Nadeem, Omar, additional, Hu, Bonnie Y., additional, Laubach, Jacob P., additional, Branagan, Andrew R., additional, Anderson, Kenneth C., additional, Mo, Clifton C., additional, Munshi, Nikhil C., additional, Ghobrial, Irene M., additional, Sperling, Adam S., additional, Agyemang, Emerentia A., additional, Burke, Jill N., additional, Harrington, Cynthia C., additional, Richardson, Paul G., additional, Raje, Noopur S., additional, and El‐Jawahri, Areej, additional

Published
2022
Full Text
View/download PDF

22. Mapping Myeloma: A Roadmap of Daratumumab Use in Clinical Pathways

Author

Hossain, Shahrier, primary, Leblebjian, Houry, additional, Jackman, David M, additional, Laubach, Jacob P., additional, Mo, Clifton C., additional, Richardson, Paul G., additional, Foster, Emily, additional, Martin-Quashie, Ariel, additional, Redd, Robert, additional, and Nadeem, Omar, additional

Published
2021
Full Text
View/download PDF

23. A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Author

Nadeem, Omar, primary, Redd, Robert A., additional, Prescott, Julia, additional, Tague, Kelsey, additional, Romines, Veronica, additional, Metivier, Amada, additional, Savell, Alexandra, additional, Leblebjian, Houry, additional, Distaso, Alexandra, additional, Mo, Clifton C, additional, Laubach, Jacob P., additional, Sperling, Adam S., additional, Richardson, Paul G., additional, and Ghobrial, Irene M., additional

Published
2021
Full Text
View/download PDF

24. Novel Cytokine-Mediated Mechanism of Action Identified By Quantitative Seroproteomics in Multiple Myeloma Patients Treated with Tagraxofusp, a Novel CD123-Directed Targeted Therapy

Author

Ray, Arghya, primary, Mo, Clifton C., additional, DU, Ting, additional, Olguin, Arturo, additional, Chen, Janice, additional, Brooks, Christopher L, additional, Mughal, Tariq I., additional, Richardson, Paul G., additional, Chauhan, Dharminder, additional, and Anderson, Kenneth C., additional

Published
2021
Full Text
View/download PDF

25. A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Author

O'Donnell, Elizabeth K., primary, Mo, Clifton C., additional, Yee, Andrew J., additional, Nadeem, Omar, additional, Branagan, Andrew R., additional, Laubach, Jacob P., additional, Gammon, Marilyn T., additional, Lively, Kathleen J., additional, Packer, Lisette, additional, Harrington, Cynthia C., additional, Agyemang, Emerentia, additional, Spillane, Kerry, additional, LaStofka, Brenton, additional, Rosenblatt, Jacalyn, additional, Raje, Noopur S., additional, and Richardson, Paul G., additional

Published
2021
Full Text
View/download PDF

26. A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Author

Nadeem, Omar, primary, Redd, Robert A., additional, Barth, Peter, additional, Mo, Clifton C, additional, Laubach, Jacob P., additional, Bianchi, Giada, additional, Bayliss, Trevor J., additional, Sanchorawala, Vaishali, additional, Shune, Leyla, additional, Distaso, Alexandra, additional, Dalton, Virginia, additional, McKenney, Mary, additional, Patches, Sarah, additional, Hou, Isabella, additional, Issokson, Lindsay, additional, Barrell, Anna, additional, Masone, Kelly, additional, Sperling, Adam S., additional, Munshi, Nikhil C., additional, Ghobrial, Irene M., additional, Anderson, Kenneth C., additional, and Richardson, Paul G., additional

Published
2021
Full Text
View/download PDF

27. COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

Author

Branagan, Andrew R., primary, Lei, Matthew M, additional, Maron, Jenny S, additional, Yee, Andrew J, additional, O'Donnell, Elizabeth, additional, Castillo, Jorge J., additional, Raje, Noopur S., additional, Treon, Steven P, additional, Flynn, Catherine A, additional, Mo, Clifton C., additional, Nadeem, Omar, additional, Richardson, Paul G., additional, Panaroni, Cristina, additional, Meid, Kirsten, additional, Bernstein, Zachary S., additional, Lyons, Rebecca T., additional, Hunter, Zachary R, additional, Guerrera, Maria Luisa, additional, Gammon, Marilyn T., additional, Lively, Kathleen J., additional, Packer, Lisette, additional, Waterman, Matthew, additional, Gallagher, Raquel, additional, Juleg, Boris, additional, Alter, Galit, additional, and Sarosiek, Shayna, additional

Published
2021
Full Text
View/download PDF

28. A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)

Author

O'Donnell, Elizabeth K., primary, Suman, Vera Jean, additional, Geyer, Susan M., additional, Nadeem, Omar, additional, Dinner, Shira, additional, Yee, Andrew J., additional, Laubach, Jacob P., additional, Mo, Clifton C., additional, Tuchman, Sascha A., additional, Donadio, Kristen, additional, Sinclair, Sarah, additional, Raje, Noopur S., additional, and Richardson, Paul G., additional

Published
2021
Full Text
View/download PDF

29. Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform

Author

Sperling, Adam S., primary, Nikiforow, Sarah, additional, Nadeem, Omar, additional, Mo, Clifton C, additional, Laubach, Jacob P., additional, Anderson, Kenneth C., additional, Alonso, Alejandro, additional, Ikegawa, Shuntaro, additional, Prabhala, Rao, additional, Hernandez Rodriguez, Diego, additional, Daley, Heather, additional, Shaw, Kit L., additional, Arihara, Yohei, additional, Ansari, Soudeh, additional, Quinn, David S, additional, Pearson, David, additional, Hack, Anniesha, additional, Treanor, Louise M, additional, Bu, Dexiu, additional, Mataraza, Jennifer, additional, Rispoli, Lawrence, additional, Credi, Marc, additional, Ritz, Jerome, additional, De Vita, Serena, additional, and Munshi, Nikhil C., additional

Published
2021
Full Text
View/download PDF

30. B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Author

Nadeem, Omar, primary, Redd, Robert A., additional, Prescott, Julia, additional, Metivier, Amada, additional, Tague, Kelsey, additional, Romines, Veronica, additional, Bertoni, Meredith, additional, Savell, Alexandra, additional, Medina, Rebekah, additional, Distaso, Alexandra, additional, Leblebjian, Houry, additional, Mo, Clifton C., additional, Laubach, Jacob P., additional, Sperling, Adam S., additional, Richardson, Paul G., additional, and Ghobrial, Irene M., additional

Published
2021
Full Text
View/download PDF

31. Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma

Author

O'Donnell, Elizabeth K., primary, Shapiro, Yael, additional, Nadeem, Omar, additional, Yee, Andrew J., additional, Laubach, Jacob P., additional, Branagan, Andrew R., additional, Anderson, Kenneth C., additional, Mo, Clifton C., additional, Munshi, Nikhil C., additional, Ghobrial, Irene M., additional, Sperling, Adam S., additional, Agyemang, Emerentia, additional, Harrington, Cynthia C., additional, Burke, Jill N., additional, Richardson, Paul G., additional, Raje, Noopur S., additional, and El-Jawahri, Areej, additional

Published
2021
Full Text
View/download PDF

32. High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the Promise Study

Author

El-Khoury, Habib, primary, Alberge, Jean-Baptiste, additional, Barr, Hadley, additional, Murphy, Ciara, additional, Sakrikar, D.J., additional, Krause, Tara, additional, Barnidge, David, additional, Bustoros, Mark, additional, Leblebjian, Houry, additional, Cowan, Annie, additional, Davis, Maya, additional, Amstutz, Julia, additional, Perry, Jacqueline, additional, Boehner, Cody J., additional, Lightbody, Elizabeth D., additional, Mouhieddine, Tarek H, additional, Sklavenitis-Pistofidis, Romanos, additional, Perkins, Mark C, additional, Harding, Stephen, additional, Kapoor, Prashant, additional, Mo, Clifton C., additional, Murray, David L., additional, Borrello, Ivan M., additional, Getz, Gad, additional, Rebbeck, Timothy R, additional, Marinac, Catherine R., additional, and Ghobrial, Irene M., additional

Published
2021
Full Text
View/download PDF

33. Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma

Author

O'Donnell, Elizabeth K., primary, Shapiro, Yael, additional, Nadeem, Omar, additional, Yee, Andrew J., additional, Laubach, Jacob P., additional, Branagan, Andrew R., additional, Anderson, Kenneth C., additional, Mo, Clifton C., additional, Munshi, Nikhil C., additional, Ghobrial, Irene M., additional, Sperling, Adam S., additional, Agyemang, Emerentia, additional, Burke, Jill N., additional, Harrington, Cynthia C., additional, Richardson, Paul G., additional, Raje, Noopur S., additional, and El-Jawahri, Areej, additional

Published
2021
Full Text
View/download PDF

34. A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Author

Nadeem, Omar, primary, Redd, Robert A., additional, Koontz, Michael Z., additional, Matous, Jeffrey V., additional, Yee, Andrew J., additional, Zonder, Jeffrey A., additional, Kin, Andrew, additional, Rosenblatt, Jacalyn, additional, Prescott, Julia, additional, Tague, Kelsey, additional, Romines, Veronica, additional, Bertoni, Meredith, additional, Metivier, Amada, additional, Medina, Rebekah, additional, Savell, Alexandra, additional, Leblebjian, Houry, additional, Distaso, Alexandra, additional, Mo, Clifton C, additional, Laubach, Jacob P., additional, Sperling, Adam S., additional, Richardson, Paul G., additional, and Ghobrial, Irene M., additional

Published
2021
Full Text
View/download PDF

35. Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group

Author

Moraleda, Jose M., Carlo-Stella, Carmelo, Garcia-Bernal, David, Jara Rubio, Ruben, Andreu, Enriqueta, Calabretta, Eleonora, Aghemo, Alessio, Diaz-Ricart, Maribel, Palomo, Marta, Carreras, Enric, Vlodavsky, Israel, Iacobelli, Massimo, Fareed, Jawed, Castro, Pedro, Fernandez, Sara, Mo, Clifton C., Weinhouse, Gerald L., Cooke, Kenneth R., Soiffer, Robert J., Baron, Rebecca M., O'Gorman, Peter, Yanik, Gregory, Pagliuca, Antonio, and Richardson, Paul G.

Published
2020
Full Text
View/download PDF

37. Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma

Author

Nadeem, Omar, Magidson, Sophie, Midha, Shonali, O'Donnell, Elizabeth K., Hartley-Brown, Monique A, Sperling, Adam S., Redd, Robert A., Marto, Marjorie, Davie, Christine, Ricciardi, Caroline, Choden, Dechen, Strutevant, Ashlee, Alberti, Jillian, Mo, Clifton C., Laubach, Jacob, Richardson, Paul G., Anderson, Kenneth C., Munshi, Nikhil C, Trippa, Lorenzo, and Ghobrial, Irene M.

Published
2023
Full Text
View/download PDF

38. Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Author

Houde, Christiane A., Khan, Abdullah, Jacobus, Susanna J., Hassoun, Hani, Anderson, Larry D., Jr., Merz, Lauren E., Zon, Rebecca L., Efebera, Yvonne, Buck, Tondre, Innis-Shelton, Racquel D., Hartley-Brown, Monique A, Lonial, Sagar, Campagnaro, Erica L., Voorhees, Peter M., Orlowski, Robert Z., Libby, Edward, Hurd, David Duane, Costello, Caitlin L., Raje, Noopur S., Medvedova, Eva, McCarthy, Philip L., Milner, Carter P., Gasparetto, Cristina, Agha, Mounzer E, Gowin, Krisstina, Kamble, Rammurti T., Jagannath, Sundar, Nathwani, Nitya, Alsina, Melissa, Giralt, Sergio A., Laubach, Jacob P., Nadeem, Omar, Ghobrial, Irene M., Mo, Clifton C., Samur, Mehmet K., Anderson, Kenneth C., Munshi, Nikhil C, and Richardson, Paul G.

Published
2023
Full Text
View/download PDF

40. Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Author

Nadeem, Omar, Magidson, Sophie, Redd, Robert A., Laubach, Jacob, Mo, Clifton C., O'Donnell, Elizabeth K., Sperling, Adam S., Hartley-Brown, Monique A, Midha, Shonali, Marto, Marjorie, Davie, Christine, Ricciardi, Caroline, Choden, Dechen, Strutevant, Ashlee, Alberti, Jillian, Trippa, Lorenzo, Munshi, Nikhil C, Anderson, Kenneth C., Richardson, Paul G., and Ghobrial, Irene M.

Published
2023
Full Text
View/download PDF

41. Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.

Author

Shapiro, Yael N., primary, Nadeem, Omar, additional, Yee, Andrew Jenho, additional, Laubach, Jacob, additional, Branagan, Andrew R., additional, Anderson, Kenneth Carl, additional, Mo, Clifton C., additional, Munshi, Nikhil C., additional, Ghobrial, Irene M., additional, Sperling, Adam Samuel, additional, Mesa, Michelle M., additional, Burke, Jill N., additional, Harrington, Cynthia C., additional, Agyemang, Emerentia A., additional, Packer, Lisette R., additional, Richardson, Paul G., additional, Raje, Noopur S., additional, El-Jawahri, Areej, additional, and O'Donnell, Elizabeth, additional

Published
2021
Full Text
View/download PDF

42. Prevalence of Monoclonal Gammopathies Including an Age-Related Monoclonal Gammopathy of Indeterminate Potential (MGIP) in a Racially Diverse US Population Screened by Mass Spectrometry

Author

El-Khoury, Habib, primary, Lee, David J., additional, Alberge, Jean-Baptiste, additional, Redd, Robert, additional, Cea-Curry, Christian J., additional, Perry, Jacqueline, additional, Barr, Hadley, additional, Murphy, Ciara, additional, Sakrikar, Dhananjay, additional, Barnidge, David, additional, Leblebjian, Houry, additional, Cowan, Anna, additional, Davis, Maya I., additional, Amstutz, Julia, additional, Boehner, Cody J., additional, Lightbody, Elizabeth D., additional, Sklavenitis-Pistofidis, Romanos, additional, Perkins, Mark C., additional, Harding, Stephen, additional, Mo, Clifton C., additional, Weiss, Scott T., additional, Karlson, Elizabeth W., additional, Trippa, Lorenzo, additional, Getz, Gad, additional, Marinac, Catherine R., additional, and Ghobrial, Irene, additional

Published
2021
Full Text
View/download PDF

43. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: A prospective cohort study

Author

El-Khoury, Habib, primary, Lee, David J., additional, Alberge, Jean-Baptiste, additional, Redd, Robert, additional, Cea-Curry, Christian J., additional, Perry, Jacqueline, additional, Barr, Hadley, additional, Murphy, Ciara, additional, Sakrikar, Dhananjay, additional, Barnidge, David, additional, Bustoros, Mark, additional, Leblebjian, Houry, additional, Cowan, Anna, additional, Davis, Maya I., additional, Amstutz, Julia, additional, Boehner, Cody J., additional, Lightbody, Elizabeth D., additional, Sklavenitis-Pistofidis, Romanos, additional, Perkins, Mark C., additional, Harding, Stephen, additional, Mo, Clifton C., additional, Kapoor, Prashant, additional, Mikhael, Joseph, additional, Borrello, Ivan, additional, Fonseca, Rafael, additional, Weiss, Scott T., additional, Karlson, Elizabeth W., additional, Trippa, Lorenzo, additional, Rebbeck, Timothy, additional, Getz, Gad, additional, Marinac, Catherine R., additional, and Ghobrial, Irene, additional

Published
2021
Full Text
View/download PDF

45. A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action

Author

Ray, Arghya, primary, Song, Yan, additional, DU, Ting, additional, Mo, Clifton C., additional, Olguin, Arturo, additional, Chen, Janice, additional, Brooks, Christopher, additional, Mughal, Tariq I., additional, Richardson, Paul G., additional, Chauhan, Dharminder, additional, and Anderson, Kenneth, additional

Published
2020
Full Text
View/download PDF

46. A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

Author

Nadeem, Omar, primary, Mo, Clifton C, additional, Laubach, Jacob P., additional, Bianchi, Giada, additional, Redd, Robert, additional, Barth, Peter, additional, Bayliss, Trevor J., additional, Sanchorawala, Vaishali, additional, Shune, Leyla, additional, Distaso, Alexandra, additional, Dalton, Virginia, additional, Sperling, Adam S, additional, Amweg, Laura, additional, McKenney, Mary, additional, Colson, Kathleen, additional, Millard, Ella L, additional, Hou, Isabella, additional, Savell, Alexandra, additional, Masone, Kelly, additional, Munshi, Nikhil C., additional, Ghobrial, Irene M., additional, Anderson, Kenneth, additional, and Richardson, Paul G., additional

Published
2020
Full Text
View/download PDF

48. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma.

Author

O'Donnell, Elizabeth K., Shapiro, Yael N., Yee, Andrew J., Nadeem, Omar, Hu, Bonnie Y., Laubach, Jacob P., Branagan, Andrew R., Anderson, Kenneth C., Mo, Clifton C., Munshi, Nikhil C., Ghobrial, Irene M., Sperling, Adam S., Agyemang, Emerentia A., Burke, Jill N., Harrington, Cynthia C., Richardson, Paul G., Raje, Noopur S., and El‐Jawahri, Areej

Abstract

Background: Multiple myeloma (MM) is an incurable hematologic malignancy requiring long‐term, continuous therapy. Despite its chronic and unrelenting course, studies examining quality of life (QOL), psychological distress, and perceptions of prognosis by line of therapy are lacking. Methods: The authors conducted a cross‐sectional, multisite study of patients undergoing treatment for MM (excluding maintenance) between June 2020 and January 2021. The authors conducted purposeful sampling and recruited patients to 3 cohorts based on lines of therapy: 1) newly diagnosed receiving first‐line therapy; 2) 2 to 3 lines; and 3) 4 or more lines. Patients completed validated questionnaires to assess their QOL, fatigue, psychological distress, and perceptions of prognosis. Results: A total of 180 patients with MM were enrolled (newly diagnosed [n = 60], 2 to 3 lines [n = 60], and ≥4 lines of therapy [n = 60]). QOL, symptom burden, and fatigue scores did not differ by lines of therapy. There were no statistically significant differences in psychological distress by line of therapy. The rates of clinically significant depression, anxiety, and post‐traumatic stress disorder symptoms were 23.9% (43 of 180), 23.9% (43 of 180), and 24.4% (44 of 180), respectively. Most patients (84.7%, 149 of 176) reported that their oncologist told them their cancer was incurable, but only 30.6% (53 of 173) acknowledged that they were terminally ill, and 42.0% (73 of 174) reported that they thought their cancer was incurable. Conclusions: Patients with MM undergoing treatment experience impaired QOL and elevated psychological distress across the disease continuum, regardless of line of therapy. A substantial proportion of patients with MM have significant misperceptions about their prognosis and the curability of their illness despite reporting being informed of the prognosis by their oncologist. Lay Summary: This study discusses 180 patients with MM (newly diagnosed [n = 60], 2‐3 lines [n = 60], and ≥4 lines of therapy [n = 60]). Quality of life, symptom burden, and fatigue scores do not differ by lines of therapy. There are also no statistically significant differences in psychological distress by line of therapy.The rates of clinically significant depression, anxiety, and post‐traumatic stress disorder symptoms are 23.9%, 23.9%, and 24.4%, respectively.Most patients (84.7%) report that their oncologist told them their cancer was incurable, but only 30.6% acknowledge that they are terminally ill, and 42.0% report that they thought their cancer was incurable. Patients with multiple myeloma undergoing treatment experience impaired quality of life and elevated psychological distress across the disease continuum. Although the majority reported that their oncologist had told them that their cancer is incurable, a substantial proportion still reported that they believed their cancer was curable. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Pomalidomide in lenalidomide‐refractory multiple myeloma: Far from futile.

Author

Mo, Clifton C. and Richardson, Paul G.

Subjects
*MULTIPLE myeloma, *PATIENT selection, *PLASMACYTOMA
Abstract

Although the results of MM-014 Cohort A strongly and encouragingly suggest that they do, the ongoing phase 2 Alliance study of pomalidomide-dexamethasone with or without ixazomib for patients who are refractory to lenalidomide in the first line (NCT02004275), will hopefully provide further confirmatory evidence to this end (Voorhees I et al i , [8]). In the context of the relevant studies of pomalidomide in multiple myeloma to date, the data collectively suggest that consideration of cytogenetic risk is important for, if not critical to, the informed selection of treatment regimens for patients with relapsed/refractory disease. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor-based therapy: phase I results. [Extracted from the article]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results